The saponification of lauric acid with calcium soaps as an alternative to in-feed antibiotics in post-weaning piglets

In the search for the reduction of antibiotics in farm animals, a concept was developed based on studies with medium-chain fatty acid with 6-12 atoms (MCFA). In particular, they have been shown to exhibit against Gram+ bacteria in piglets at relatively high concentrations. However they can be hardly used as such because of their repellent odour and taste and for their rapid absorption in upper gastrointestinal tract. These problems could be overcome by the generation of monoacylglycerol, but esterification is usually carried out on a silica base, which reduces the concentration of FA, therefore limiting the antibacterial effects. Our hypothesis is that the saponification with calcium salts might positively affect their concentration in the GIT. The aim of the present study was to examine the effects of Laurate calcium soap (C12-Ca soap) on growth performance and health of post-weaning piglets. At weaning, 192 crossbreed Topics piglets were assigned to 3 experimental groups consisting of 16 pens (4 pigs/pen each): CTR (negative control), T1 (basal diet plus Amoxycillin at 400 mg/kg), and T2 (basal diet plus C12-Ca soap at 1 kg/ton). Gain and feed consumption did not differ among groups. Feed efficiency was higher in T1 (0,61) and T2 (0,58) than CTR (0,51) (P<0,01). Mortality was 0 in T1, and reduced in T2 (4,7%) compared to CTR (10,9%). These preliminary results suggest that saponification of MCFA may be a valuable alternative to in-feed antibiotics, used for growth promotion, and even for enhancing health in post-weaning piglets

COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

Background and objectives: It is unclear how multiple sclerosis (MS) affects the severity of COVID-19. The aim of this study is to compare COVID-19-related outcomes collected in an Italian cohort of patients with MS with the outcomes expected in the age- and sex-matched Italian population. Methods: Hospitalization, intensive care unit (ICU) admission, and death after COVID-19 diagnosis of 1,362 patients with MS were compared with the age- and sex-matched Italian population in a retrospective observational case-cohort study with population-based control. The observed vs the expected events were compared in the whole MS cohort and in different subgroups (higher risk: Expanded Disability Status Scale [EDSS] score > 3 or at least 1 comorbidity, lower risk: EDSS score ≤ 3 and no comorbidities) by the χ2 test, and the risk excess was quantified by risk ratios (RRs). Results: The risk of severe events was about twice the risk in the age- and sex-matched Italian population: RR = 2.12 for hospitalization (p < 0.001), RR = 2.19 for ICU admission (p < 0.001), and RR = 2.43 for death (p < 0.001). The excess of risk was confined to the higher-risk group (n = 553). In lower-risk patients (n = 809), the rate of events was close to that of the Italian age- and sex-matched population (RR = 1.12 for hospitalization, RR = 1.52 for ICU admission, and RR = 1.19 for death). In the lower-risk group, an increased hospitalization risk was detected in patients on anti-CD20 (RR = 3.03, p = 0.005), whereas a decrease was detected in patients on interferon (0 observed vs 4 expected events, p = 0.04). Discussion: Overall, the MS cohort had a risk of severe events that is twice the risk than the age- and sex-matched Italian population. This excess of risk is mainly explained by the EDSS score and comorbidities, whereas a residual increase of hospitalization risk was observed in patients on anti-CD20 therapies and a decrease in people on interferon

DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France

We evaluated the effect of DMTs on Covid-19 severity in patients with MS, with a pooled-analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid-19 severity was assessed by multivariate ordinal-logistic models and pooled by a fixed-effect meta-analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti-CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid-19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled-analysis confirms an increased risk of severe Covid-19 in patients on anti-CD20 therapies and supports the protective role of interferon

Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting

Increasing numbers of drugs are being developed for the treatment of multiple sclerosis (MS). Measurement of relevant outcomes is key for assessing the efficacy of new drugs in clinical trials and for monitoring responses to disease-modifying drugs in individual patients. Most outcomes used in trial and clinical settings reflect either clinical or neuroimaging aspects of MS (such as relapse and accrual of disability or the presence of visible inflammation and brain tissue loss, respectively). However, most measures employed in clinical trials to assess treatment effects are not used in routine practice. In clinical trials, the appropriate choice of outcome measures is crucial because the results determine whether a drug is considered effective and therefore worthy of further development; in the clinic, outcome measures can guide treatment decisions, such as choosing a first-line disease-modifying drug or escalating to second-line treatment. This Review discusses clinical, neuroimaging and composite outcome measures for MS, including patient-reported outcome measures, used in both trials and the clinical setting. Its aim is to help clinicians and researchers navigate through the multiple options encountered when choosing an outcome measure. Barriers and limitations that need to be overcome to translate trial outcome measures into the clinical setting are also discussed

Effects of dietary yeast-derived nucleotide and RNA on growth performance, survival, immune responses, and resistance to Vibrio parahaemolyticus infection in Pacific white shrimp (Litopenaeus vannamei)

Nucleotides (NT) and RNA from yeast extracts are gaining interest as high-value feed additives. The present study intended to evaluate the influences of yeast derived-NT and RNA on the growth performance, survival, immune responses, and resistance to Vibrio parahaemolyticus infection in Pacific white shrimp. In Experiment 1, postlarvae were distributed into 7 groups, corresponding to 7 experimental diets: control, NT 0.25, NT 0.50, NT 0.75, RNA 0.25, RNA 0.50, and RNA 0.75 g/kg feed. They were fed the experimental diets for 45 days. Then, their body weights, survival rates, immune parameters, and Vibrio spp. counts in the hepatopancreas and intestines were determined. In Experiment 2, the shrimp from Experiment 1 were challenged by immersion with V. parahaemolyticus at 105 CFU/mL. Each group was fed the same diet for another 10 days to assess the disease resistance performance. The results revealed that the shrimp body weights of all groups were similar suggesting that neither NT nor RNA exerts the growth-promoting effect. However, the average survival rates of the NT and RNA groups were in the range of 89–93 %, significantly higher than that of the control (83 %). These increased survivals were in line with the reduction in the hepatopancreatic and intestinal Vibrio spp. counts and the elevated immune parameters in the NT and RNA-fed shrimp. At day 10 after the bacterial challenge, the highest survival rates were observed in the RNA 0.50 and 0.75 g/kg feed groups (81 % and 82 %, respectively), followed by the RNA 0.25 (70 %) and NT 0.75 g/kg feed (68 %), and significantly higher than the positive control (54 %). In short, both yeast-derived NT and RNA, especially the RNA at the dose of 0.50–0.75 g/kg feed groups, showed promising health benefits effects in the Pacific white shrimp, notably the improved immune function and disease resistance

Live Yeast Supplementation in Gestating and Lactating Primiparous Sows Improves Immune Response in Dams and Their Progeny

The present study determined the effects of live yeast (LY) supplementation during middle–late gestation and the lactation period in primiparous sows on reproductive parameters, lactation performance, and immunity, and also explores the carryover effects in their offspring. On day (d) 60 of gestation, 16 crossbred primiparous sows were randomly assigned to two dietary treatments (with or without supplementation of 425 mg/kg of live yeast; LYT and CT, respectively) homogeneous for body weight (BW) and backfat thickness. Experimental diets were applied from day 60 of gestation to the end of lactation. At weaning, 60 piglets with an average BW of each treatment were selected based on their source litter and assigned to two groups corresponding to the original treatments received by their mothers. Each group had five replicates of six piglets each and was fed a basal diet for 42 days. The results showed that LY supplementation significantly increased the serum IgA and IgG concentrations of sows at farrowing and weaning stages, and of piglets on day 14 and 28 post weaning. No significant differences were found in reproductive and lactation performance, while minor effects were observed on antioxidant capacity. In conclusion, live yeast addition during middle–late gestation and the whole lactation period resulted in enhanced immunity of primiparous sows and their offspring, therefore, improving maternal and progeny health

The Role of Yeast Saccharomyces cerevisiae in Supporting Gut Health in Horses: An Updated Review on Its Effects on Digestibility and Intestinal and Fecal Microbiota

To support the overall health of horses, it is essential to maintain an optimal gut health (GH) status, which encompasses several physiological and functional aspects, including the balance and functionality of intestinal microbial populations and, accordingly, the effective digestion and absorption of nutrients. Numerous biotic and abiotic stressors can lead to an imbalance of GH, such as the quality of forages and the composition of diet, e.g., the inclusion of high energy-dense feeds to meet the energy requirements of performance horses. To support the digestive function and the intestinal microbial populations, the diet can be supplemented with feed additives, such as probiotic yeasts, that promote the ability of cellulolytic bacteria in the hindgut to digest the available fiber fractions, finally increasing feed efficiency. Among the different yeasts available, S. cerevisiae is the most used in horses’ nutrition; however, results of digestibility trials, as well as data on intestinal and fecal microbial populations, are sometimes contradictory. Therefore, the purpose of this review is to summarize the effects of S. cerevisiae on in vivo and in vitro digestibility, providing an updated overview of its effects on the intestinal and fecal microbial population

Green Tea and Pomegranate Extract Administered During Critical Moments of the Production Cycle Improves Blood Antiradical Activity and Alters Cecal Microbial Ecology of Broiler Chickens

Phytobiotics are usually tested in feed and throughout the production cycle. However, it could be beneficial to evaluate their effects when administered only during critical moments, such as changes in feeding phases. The aim of the trial was to investigate the effect of a commercial plant extract (PE; IQV-10-P01, InQpharm Animal Health, Kuala Lumpur, Malaysia) on growth performance, blood antiradical activity and cecal microbiome when administered in drinking water to broiler chickens during the post-hatching phase and at each change of diet. In the experiment, 480 1-day-old male broiler chicks were assigned to two groups in a 50-day trial. Broilers received drinking water (C) or drinking water plus PE (T) at a rate of 2 mL/L on days 0 to 4, 10–11 and 20–21. PE did not affect performance and water intake, while total antiradical activity was improved (p < 0.05). A greater abundance of lactic acid bacteria (false discovery rate (FDR) < 0.05) was found in the T group and the result was confirmed at a lower taxonomic level with higher Lactobacillaceae abundance (FDR < 0.05). Our findings suggest that PE administration during critical moments of the production cycle of broiler chickens may exert beneficial effects at a systemic level and on gut microbial ecology